Related Experiment Video
Updated: Jan 15, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.9K
[New anticoagulants: better knowledge, better prescriptions].
1Unité d'hémostase, Service d'angiologie et d'hémostase, Département des spécialités de médecine, HUG, 1211 Genève 14. francoise.boehlen@hcuge.ch
Revue Medicale Suisse
|November 29, 2012
Summary
New oral anticoagulants offer effective and safe options for preventing and treating blood clots and atrial fibrillation. While they may replace some older drugs, traditional anticoagulants will remain important for years to come.
Area of Science:
- Pharmacology
- Cardiology
- Hematology
Context:
- Emerging availability of novel oral anticoagulants (NOACs).
- Established efficacy and safety profiles of NOACs in key clinical areas.
- Potential shift in anticoagulant prescribing patterns.
Purpose:
- To review the efficacy and safety of new oral anticoagulants.
- To discuss the implications of NOACs on current anticoagulant therapy.
- To highlight considerations for the integration of NOACs into clinical practice.
Summary:
- New oral anticoagulants demonstrate significant efficacy and safety in preventing and treating venous thromboembolism and managing atrial fibrillation.
- These agents are poised to alter the landscape of anticoagulant prescriptions, potentially supplanting vitamin K antagonists.
- Clinical use requires caution pending post-marketing surveillance, and established anticoagulants will retain a role.
Impact:
- Anticipated modification of anticoagulant prescribing habits.
- Continued relevance of traditional anticoagulants alongside novel agents.
- Need for ongoing research and post-marketing evaluation of NOACs.
Related Concept Videos
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
01:29Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
01:27Coronary Artery Disease V: Interprofessional Care
212
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
212
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K